NaPDI

The Center of Excellence for Natural Product-Drug Interaction Research (NaPDI) conducts research on the clinical relevance of natural product-drug interactions.

[NaPDI @NaPDICenter]

Contribute to research! Researchers @WSUPharmacy @WSUSpokane seek healthy adults 21-45yo to participate in a kratom-drug interaction study. Consists of 4 study arms (est 52hrs over 8 wks). Subjects earn up to $1,400 for completing the study. Learn more at https://t.co/6cRYdaBDHA.

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYiiS6I #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYijpWg #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYiiS6I #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYijpWg #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYiiS6I #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYijpWg #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYiiS6I #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYijpWg #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYiiS6I #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYijpWg #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYiiS6I #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

This study investigated the use of limited sampling strategies with fexofenadine to assess transporter activity in healthy adults. The research found that the current fexofenadine limited sampling models using single-timepoint, 2-timepoint, and partial AUC measurements were not reliable for accurately estimating systemic exposure. This suggests that more complex approaches may be needed for future transporter-mediated drug-drug interaction studies. Published in International Journal of Clinical Pharmacology and Therapeutics (2023) Liyanage, Blaquera, Piscitelli et al https://t.co/l73qYijpWg #pharmacokinetics #drugmetabolism #DDI #drugdevelopment #research #clinicalpharmacology #transporterphenotyping

[NaPDI @NaPDICenter]

Kratom Alkaloids: A tale of two configurations This study reveals significant differences in pharmacokinetic behavior between kratom alkaloids with the 3S and 3R configuration. These findings suggest potential variations in how the body processes different kratom compounds. Published in Pharmaceutics by Tanna, Nguyen, Hadi, Manwill et al https://t.co/axQxnp06nh #kratom #pharmacology #alkaloids #mitragynine #diastereomers #research

[NaPDI @NaPDICenter]

Challenges in developing a limited sampling strategy for Fexofenadine Despite its potential, the study found that a limited sampling strategy for fexofenadine was unable to accurately estimate fexofenadine AUC and therefore could not reliably estimate P-gp and OATP1B1/3 activity. This suggests that further research is needed to identify more effective methods for evaluating these transporters. Published in Therapeutic Drug Monitoring (2024) by Piscitelli, Nikanjam, Capparelli et al https://t.co/kqH4Lo5njO #pharmacology #druginteractions #fexofenadine #Pgp #OATP #limitedsampling #research

[NaPDI @NaPDICenter]

Model predicts cannabidiol (CBD) levels in the body A physiologically-based pharmacokinetic (PBPK) model has been developed to predict how CBD is processed in the body. This model can be used to understand how CBD interacts with other medications and how it might be affected by factors like liver function and age. Published in Drug Metabolism and Disposition by Bansal, Ladumor, Paine and Unadkat https://t.co/fgFMorVKEn #CBD #PBPK #Pharmacokinetics #DrugInteractions #HepaticImpairment #Children

[NaPDI @NaPDICenter]

While this study highlights a potential interaction between green tea and certain medications, further research is needed to understand the full implications for other drugs and individual patients. Published in Pharmaceutical Research (2024) by Oyanna, Bechtold, Lynch et al https://t.co/YPhwUaCHyC #pharmacokinetics #green tea extract #drug interaction #EGCG #osteoporosis #medication

[NaPDI @NaPDICenter]

The study reveals that the interaction between goldenseal and midazolam primarily occurs in the intestines, not the liver. This emphasizes the importance of considering potential drug interactions when taking supplements, especially for medications metabolized by intestinal CYP3A enzymes. Published in Journal of Pharmacology and Experimental Therapeutics (2023) by Nguyen, Tian, Tanna, Arian et al https://t.co/qMyBZVDyno #goldenseal #druginteractions #CYP3A #intestines #liver #health #medication #science #pharmacokinetics

[NaPDI @NaPDICenter]

Bridging the gap in natural product safety research: Improving data collection with AI-powered string matching Accurate data collection is crucial for understanding the safety of natural products. This study explored the effectiveness of a combined fuzzy string-matching and Siamese neural network approach to identify natural products in the FAERS database. The results highlight the potential of AI to enhance pharmacovigilance and improve patient safety. Published in Scientific Reports (2024) by Dilán-Pantojas, Boonchalermvichien, Taneja, et al https://t.co/Bz8ePO5OL4 #naturalproducts #AI #pharmacovigilance #FAERS #data #research #safety #health

[NaPDI @NaPDICenter]

PheKnowLator: Benchmarking and evaluating biomedical knowledge graphs A key challenge in KG research is the lack of comprehensive benchmarks for evaluating KG construction methods and their impact on downstream analyses. PheKnowLator provides a set of pre-built benchmark KGs in various formats and with accompanying embeddings, enabling researchers to systematically assess the effects of different knowledge representations on their work. Published in Scientific Data (2024) by Callahan, Tripodi, Stefanski et al https://t.co/OPWrzLeIf5 #bioinformatics #knowledgegraph #benchmarks #dataanalysis #machinelearning #graphrepresentation #graphlearning

[NaPDI @NaPDICenter]

Green tea: More than just a healthy drink? While green tea is generally considered beneficial, this study reveals that it could potentially affect the absorption of some drugs. The study explored the interaction between green tea and raloxifene, finding a significant decrease in raloxifene's systemic exposure. Published in Clinical and Translational Science (2023) by Clarke, Judson, Tian, et al https://t.co/KhjWW7xrYP #pharmacokinetics #drugabsorption #green tea #health #researc